Microbiology: Coverage

MIC break points established by the CLSI for ZINFORO^®:
 

In vitro susceptibility testing break points^1,2

MIC break points established by the EUCAST for ZINFORO^®:

In vitro susceptibility testing break points^{1,3​​​​​}

ZINFORO^® is a fifth-generation cephalosporin with coverage against key pathogens in CAP and cSSTI, including S. aureus and S. pneumoniae.^1,4

Clinical efficacy has been demonstrated against the following pathogens in cSSTI¹:​​​​​​​

*Efficacy has been demonstrated in CAP clinical studies against the following pathogens that were susceptible to ceftaroline in vitro: S. pneumoniae, S. aureus (methicillin-susceptible strains only), E. coli, H. influenzae, H. parainfluenzae and K. pneumoniae.
Efficacy has been demonstrated in clinical studies of cSSTI against pathogens that were susceptible to ZINFORO^® in vitro.^1
†The break point for susceptibility is based on a dosage regimen of ceftaroline 600 mg administered q12h.^2
‡The available clinical data cannot substantiate efficacy against PNSP. In vitro data indicate that the following atypical species are not susceptible to ZINFORO^®: Chlamydophila spp., Legionella spp., Mycoplasma spp., Proteus spp. and P. aeruginosa.^1
§Refers to dosing of adults or adolescents (from 12 years of age and weight 33 kg) with ceftaroline q12h using 1-hour infusions.^1
IIRefers to dosing of adults or adolescents (from 12 years of age and weight 33 kg) with ceftaroline q8h using 2-hour infusions to treat cSSTI.
S. aureus with ceftaroline MICs ≥4 mg/mL is rare. PK/PD analyses suggest that dosing of adults or adolescents (from 12 years of age and weight 33 kg) with ceftaroline q8h using 2-hour infusions may treat cSSTI due to S. aureus for which ceftaroline MIC is 4 mg/mL.^1
¶Inferred by susceptibility to benzylpenicillin.³


CAP, community-acquired pneumonia; CLSI, Clinical and Laboratory Standards Institute; cSSTI, complicated skin and soft tissue infection; MIC, minimum inhibitory concentration; MRSA, methicillin-resistant Staphylococcus aureus; MSSA, methicillin-sensitive Staphylococcus aureus; PD, pharmacodynamic; PNSP, penicillin-non–susceptible strains of S. pneumoniae; PK, pharmacokinetic; q8h, every 8 hours; q12h, every 12 hours.

References:​​​​​​